Navigation Links
Global Experts Explore Entire Spectrum of Aids Vaccine Development
Date:8/19/2007

More than 900 attendees from 47 countries convene in Seattle for AIDS

Vaccine 2007 Conference

SEATTLE, Aug. 20 /PRNewswire/ -- More than 900 global researchers, clinicians, and specialists convene this week for the AIDS Vaccine 2007 Conference at the Sheraton Seattle Hotel and Towers. Since the AIDS Vaccine 2000 Conference in Paris, this event has emerged as the premier forum for the exchange of scientific information relating to the difficult task of developing an effective vaccine against HIV.

"It has become clear that a preventive vaccine is essential to controlling the global AIDS epidemic," says conference chair Dr. Lawrence Corey. "The conference provides a venue for the full-scale international, interdisciplinary collaboration which is critical to the development of a global AIDS vaccine."

The week-long conference which concludes on Aug. 23 will examine the entire spectrum of issues in AIDS vaccine development and deployment: including, the global effort in preventative and therapeutic vaccines, the potential development of pediatric and adolescent vaccines, clinical trials in emerging countries, and the need for strong political and financial commitment to support the scientific development of a vaccine against AIDS.

The location of the conference in Seattle is reflective of the Pacific Northwest's international leadership in the development of an AIDS vaccine. Seattle organizations contributing to the conference include the Fred Hutchinson Cancer Research Center's HIV Vaccine Trials Network, the Seattle Biomedical Research Institute, the University of Washington and the Bill & Melinda Gates Foundation.

AIDS Vaccine 2007 is the first conference to be organized under the auspices of the Global HIV Vaccine Enterprise, (http://www.hivvaccineenterprise.org) an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Additionally, at this year's conference the Enterprise will release its first comprehensive report, detailing the successes and efforts of global AIDS vaccine research over the last four years.

"By hosting the conference the Enterprise furthers its purpose to help scientists work as a global community of problem solvers in the spirit of collaboration to move the best science forward as quickly as possible," says Dr. Jose Esparza, conference co-chair and interim head of the Enterprise.

The AIDS epidemic continues to grow as a global threat with the number of people living with HIV increasing in every region of the world. According to UNAIDS, the most striking increases have occurred in East Asia, Eastern Europe, and Central Asia, where the number of people living with HIV in 2006 was over one-fifth (21%) higher than in 2004.

About the AIDS Vaccine 2007 Conference For more information about the conference or for a complete program of the day's events, please visit the AIDS Vaccine 2007 Conference website at http://www.aidsvaccine07.org.


'/>"/>
SOURCE The AIDS Vaccine 2007 Conference

Copyright©2007 PR Newswire.

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. The state of global biotech: An Ernst & Young perspective
3. Doyle announces new energy, global warming policies
4. Lucigen Corp. enters global licensing agreement
5. Global information firm reaches diverse markets
6. Work-life imbalance - A global problem getting worse
7. Leading global Big Pharma companies of 2005
8. Learning to swim in the global talent pool
9. Federal and global guidelines on stem cell research offer a level playing field
10. Midwest life-science company Perrigo globalizes under the radar
11. The global power of WWW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):